GlaxoSmithKline Pharmaceutical Ltd (GSK Pharma) is an indian subsidiary of GlaxoSmithKline plc. It deals in prescription medicines and vaccines.Market Capitalisation
The market capitalisation of GlaxoSmithKline Pharmaceutical Ltd as on 4 July 2018 is a little over Rs.24,300 crore.
Company’s Wealth and Recent Performance
- GSK Pharma’s revenue witnessed a 4% decline at Rs.749 crore for the quarter ended (Q4 FY 2017-18)31st March 2018. The revenue was from the company’s operations and saw a decline compared to the same period a year earlier. The company recorded a profit before tax (PBT) of Rs.164 crore which increased by 14% while the profit after tax (PAT) saw a decline of 6% at Rs 106 crores as compared to the same period a year ago.
- Meanwhile, the company’s revenue for the entire financial year ended 31st March 2018 recorded a 3% decline at Rs.2,896 crores, as against the previous 12 months ended 31st March 2017. The company’s PBT was up 6% at Rs.542 crores while the PAT saw a jump of 5% at Rs.352 crores. Both the profits were high for the same period as compared to the previous year ended 31st March 2017.
- GSK Pharma reported a decline in the revenue owing to the impact of GST on the rates effective from 1 July 2017. Moreover, the revenue took a hit due to a divested and discontinued portfolio.
- A dividend of Rs.35 per equity share of Rs. 10 each was declared by the company’s Board of Director for the 12 month period ended 31 March 2018. In comparison, the dividend was Rs. 30 per share in the previous year.
- GSK Pharma launched Biopatch, a hydrophilic wound dressing in Q4 FY18. Biopatch is used to cover a wound caused by the use of percutaneous medical devices. The company is increasing the promotion of the product in a number of hospitals in all major cities in India.
- In 2017, the company announced plans to invest Rs.1,000 crore in pharmaceutical unit in Vemgal, Karnataka. As per the company’s annual report, the factory will produce over 8 billion tablets and 1 billion capsules a year.
GlaxoSmithKline Pharmaceutical Ltd. Stock Trends 2018
- On 1 January 2018, the opening price of GlaxoSmithKline Pharmaceutical Ltd. stock was Rs.2,490. It saw a marginal change throughout the month. In the month of February, the company reported over 69% jump in Q3 profit. However, this did not have a prominent effect on the price of the stock which fell by 50 points by the end of the month and was at Rs.2,384.
- In March, the scrip continued to fall throughout the month and fell by around 200 points to end the month at Rs.2,147. The scrip gained a little momentum in April and crossed Rs.2,400 in the later half of the month. The opening price of the stock by the end of April 2018 was Rs.2,334.
- The scrip was pretty flat in the month of May and witnessed a marginal increase. In June, the price of the stock crossed Rs.2,500 and continued to increase by over 300 points in the first half of the month. By the end of June 2018, the price of the stock was Rs.2,774.
GlaxoSmithKline Pharmaceutical Ltd. Stock Trends 2016 and 2017
- The opening price of the GlaxoSmithKline Pharmaceutical Ltd. stock on 1 January 2016 was Rs.3,315 on NSE. The scrip did not see a big change throughout the month. In February, the stock price saw drop of around 150 points and ended the month at Rs.3,142. The month of March saw the scrip gain momentum as it was at Rs.3,258 in the first half of the month. It further increased by more than 500 points by the end of the month. The opening price of the stock on 31 March 2018 was Rs.3,769. The scrip was stable in the month of April and did not record a huge fluctuation.
- The opening price of the stock in May was Rs.3,730 and it kept falling throughout the month by around 200 points. The scrip ended the month at Rs.3528. In the month of June, the stock price changed marginally. However, in July the stock price fell again by around 200 points and ended the month at Rs.3,325. The scrip continued its downfall throughout August and was at Rs.3,010 by the end of the month.
- In September, the price of stock started to decline even further and ended the month at Rs.2,807. The scrip gained over a 100 points in October and reached over Rs.2900 by the end of the month. In the month of November, the price of the stock decreased and by the first half of the month it had reached Rs.2,688. In December 2016, the scrip gained a little and ended the month at Rs.2,730.
- On 2 January 2018, the opening price of the stock was at Rs.2,725 and it continued to fluctuate in the same range throughout the month. It fell by around 100 points in the month of February. The scrip witnessed a marginal change in the month of March and ended the month at Rs.2,731. In April, the price of the stock fell by over 200 points and reached Rs.2,568 by the end of the month.
- In May, the stock continued to decline and fell again by over 200 points. The opening price of the stock at the end of the month was Rs.2,391. The scrip was stable in June and recorded only a marginal change. In July, the price of the stock crossed Rs.2,600 in the first half of the month but fell by over 200 points by the end of July as the company recorded 63% dip in Q1 net profit. In August, the price saw a marginal change and ended the month at Rs.2,415.
- In the month of September and October, the stock price witnessed a moderate change. By the end of October, the scrip was at Rs.2,560. The price of GSK Pharma stock crossed Rs.2,600 in the first half of November but it fell by around 200 points by the end of the month and was at Rs.2,459. In December, the share price continued to fall and ended the month at Rs.2,462.
Should you invest in GlaxoSmithKline Pharmaceutical Ltd?
- GSK Pharma is working on improving its technological capabilities in order to optimise its medical and field force engagement with healthcare professionals. The company sells around 30% of global pharmaceutical volumes in India.
- The stock of GSK Pharma has been quite volatile and has seen some major fluctuations in the past couple of years. However, the company has a been a trusted brand for a long time in the country and has some major plans for the future.
- Investing in GlaxoSmithKline Pharmaceutical Ltd. stock for a long-term purpose could be a good investment option. However, it is strongly advised that you do a strong research before investing your hard-earned money in the stock market as it is risky due to its volatile nature.
GlaxoSmithKline Pharmaceutical Ltd is one of the oldest pharmaceuticals companies in India. As mentioned earlier, the company’s product portfolio comprises of prescription medicines across on array of therapeutic areas including respiratory diseases, gynaecology, anti-infectives,diabetes, oncology, dermatology, and cardiovascular disease. On the other hand, the company offers vaccines for diseases like chickenpox, tetanus, prevention of hepatitis A, diphtheria, hepatitis B, influenzae, chickenpox,, pertussis, rotavirus, cervical cancer, invasive disease caused by H and others.
History of the company
GSK Pharmaceutical was launched in India on 13 November 1924 under the name of H.J.Foster & Co. Limited. It was founded as an Agency House for distributing Baby Food Glaxo. In 1950, the company changed its name to Glaxo Laboratories. As per the company website, the GSK Pharma has more than 4,500 employees across several manufacturing facilities, offices and field in India.
Management of the Company
Mr. Annaswamy Vaidheesh - Vice President, South Asia & Managing Director
Mr. Annaswamy Vaidheesh was appointed as the Vice President, South Asia & Managing Director of GSK Pharmaceutical Ltd. in 2015. He was previously working with Johnson & Johnson as the VP, Corporate Government Affairs for Asia-Pacific region. He is also president of the Organisation of Pharmaceutical Producers of India (OPPI). Vaidheesh completed his bachelor’s in Physics from Madras University and has a Master’s Degree in Marketing Management from Bombay University.
Listings in NSE, BSE, and Indices
The stock of GlaxoSmithkline Consumer Healthcare Ltd is available for trading on the two major stock exchanges of India - The National Stock Exchange Limited (NSE) and Bombay Stock Exchange (BSE).
The company forms a part of important indices like:
- Nifty 500
- S&P BSE 500
- S&P BSE 200
- S&P BSE Healthcare
- S&P BSE AllCap
GlaxoSmithKline Consumer Healthcare
24-25 Floor, One Horizon Center
Golf Course Road, DLF Phase 5
Gurgaon 122002, India
Tel: 000 800 442 0168
Stocks vs. Mutual Funds: here's what we recommend
Stock market investments require a lot of research and knowledge. They do not generally offer any tax benefits and are regarded as high-risk investments. Hence,it is crucial to have a diversified portfolio. At Bankbazaar, we encourage our readers to invest on mutual funds.It doesn't require a lot of knowledge and equity linked mutual fund schemes offer tax benefits. Additionally, since mutual funds comprise stocks from multiple companies, they help in building a diversified portfolio.DISCLAIMER:
The contents of this post/blog does not constitute financial or other professional advice nor does it imply in any manner a principal-agent relationship, and is not a professional advice on a specific financial matter.